Delivery Order SPE2DB22D1017-SPE2DB25FYSCP
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Promacta 75 mg tablets in quantities of 30 units. This firm fixed-price contract, valued at $36,088.89, represents a non-set-aside, competitively awarded procurement supporting federal medical supply requirements. The order is scheduled for completion by October 9, 2025, with performance originating from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $12,029.63 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Promacta 75 mg tablets in quantities of 30 units. This competitive, firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a continuation of the company's pharmaceutical supply services to the federal government. The award was executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Promacta 75 mg tablets in quantities of 30 units. This firm fixed-price contract, valued at $24,059.26, represents a non-competitive set-aside award and is scheduled for completion by August 11, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Promacta 50 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $16,053.06, represents a non-set-aside competitive award with an ultimate completion date of September 22, 2025. The pharmaceutical products will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $48,118.52 to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Promacta 75 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract calls for completion by October 10, 2025, with fulfillment from AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $12,029.63 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Promacta 75 mg tablets (30-unit packages). This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support program for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Promacta 50 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $16,053.06 and an ultimate completion date of August 26, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement valued through December...
- The Defense Logistics Agency awarded a $4,418.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Promacta 25 mg tablets (30-count units). The contract, which is a child delivery order under a larger indefinite delivery vehicle, carries an ultimate completion date of August 18, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Promacta 50 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $8,026.53 and an ultimate completion date of September 17, 2025. The contract involves no set-aside designation and was competitively awarded. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania serves as both the place of performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $12,029.63 to supply Promacta 75 mg tablets (30-count units) with a completion deadline of May 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively on April 24, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This delivery order...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYSCPDelivery Order
The Defense Logistics Agency awarded a $36,088.89 delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Promacta 75 mg tablets in quantities of 30 units. This competitive, non-set-aside contract is structured as a firm fixed price delivery order with an ultimate completion date of October 20, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen Drug Corp maintains its corporate office. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp fulfills this order under its overarching Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime vendor agreement extending through December 2026. This delivery order represents one of numerous pharmaceutical procurement transactions executed by AmerisourceBergen Drug Corp through the DLA Medical Supply Chain, which provides pharmaceutical products and medical supplies to support military healthcare systems and other federal government agencies. The company's extensive federal contract portfolio demonstrates its capability to supply specialized medications, including immunosuppressive agents such as Promacta, across multiple therapeutic domains in support of Defense Health Agency operations and other government healthcare programs. The firm fixed pricing structure and competitive award process reflect the company's established position as a qualified pharmaceutical prime vendor within the federal procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.1k | 9/26/25 |